AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 25, 2024
Researchers studied cancer growth in mice. (Zhuang et al., Nature, 2024) Aging brings two opposing trends in cancer risk: first, the risk climbs in our 60s and 70s, as decades of genetic mutations build up in our bodies.
Pharmaceutical Technology
DECEMBER 25, 2024
VMT-01 is under clinical development by Perspective Therapeutics and currently in Phase II for Metastatic Melanoma.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Commerce
DECEMBER 25, 2024
The latest in container tech and temperature-monitoring truly powered the content.
Pharmaceutical Technology
DECEMBER 25, 2024
Glufosfamide is under clinical development by Eleison Pharmaceuticals and currently in Phase III for Metastatic Adenocarcinoma of The Pancreas.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 25, 2024
Healthy brains require healthy livers. (Science Photo Library/Canva) As the global population ages, more of us face frightening cognitive decline, personally or in our loved ones. There are over 10 million new cases of dementia globally each year.
Pharmaceutical Technology
DECEMBER 25, 2024
Dexamethasone sodium phosphate SR is under clinical development by Taiwan Liposome and currently in Phase III for Osteoarthritis Pain.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
DECEMBER 25, 2024
EXO-CD24 is under clinical development by Nano24med and currently in Phase II for Acute Respiratory Distress Syndrome.
Pharmaceutical Technology
DECEMBER 25, 2024
AROC-3 is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for IgA Nephropathy (Berger's Disease).
Pharmaceutical Technology
DECEMBER 25, 2024
Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome.
Pharmaceutical Technology
DECEMBER 25, 2024
Gamma-PN is under clinical development by GPN Vaccines and currently in Phase II for Streptococcal Pneumonia.
Pharmaceutical Technology
DECEMBER 25, 2024
ACTUS-101 is under clinical development by Asklepios BioPharmaceutical and currently in Phase II for Pompe Disease.
Pharmaceutical Technology
DECEMBER 25, 2024
NB-4746 is under clinical development by Nura Bio and currently in Phase I for Amyotrophic Lateral Sclerosis.
Expert insights. Personalized for you.
130 
Let's personalize your content